Amarin Corporation - נכסים נקיים למניה בודדת AMRN

Amarin Corporation plc (AMRN) specializes in developing medications for cardiovascular protection. Historical price action reflects the current 21.30 metric, leveraging capacities in the US and Ireland, where biopharmaceutical production is strictly controlled. The brand's advantage lies in the prescription status of Vascepa, which effectively prevents strokes through purified EPA. However, the loss of patent protection has led to stagnant development and a temporary lull in updating the drug portfolio.

Book value per share reflects the amount of equity minus all liabilities, demonstrating the real value of an investor's stake based on verified assets. Analyzing the net asset value per share allows for an assessment of the fundamental stability of Amarin Corporation plc (AMRN), whose capitalization is supported by the development of the drug Vascepa through global distribution partnerships and marketing synergies.